BioCentury | Feb 23, 2021
Product Development

U.K. adds to real-world data backing flexible COVID vaccine schedule

...findings, published as a preprint in The Lancet, are consistent with Friday’s correspondence in The Lancet...
BioCentury | Feb 20, 2021
Product Development

More evidence it’s okay to delay second dose of COVID vaccines

...first and second doses.One study, reported Friday by Chaim Sheba Medical Centre and Tel Aviv University researchers in The Lancet...
...from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) rises quickly after the first dose. The second paper, also published in Lancet...
...to the window when vaccine-induced immune responses were building. New AstraZeneca dataAlso on Friday, a separate Lancet...
BioCentury | Feb 6, 2021
Product Development

AstraZeneca’s vaccine results suggest a modality-independent dip in protection against variants

...against symptomatic disease caused by the B.1.1.7 (501Y.V1) variant first identified in the U.K. in a Lancet ...
...B.1.1.7 and 95.6% against the original variant.The variant-based paper also support findings reported Monday in a Lancet paper...
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

...registered the heterologous adenoviral vector vaccine to 18. The new authorizations were announced a day after The Lancet...
BioCentury | Feb 4, 2021
Product Development

AstraZeneca’s Phase III vaccine reduces symptomatic cases, not asymptomatic spread

...problem of asymptomatic spread. The results, according to a Lancet...
...the boosterdose,” the authors wrote in the Lancet...
...down slightly from the 70.4% reported in Lancet...
BioCentury | Feb 3, 2021
Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

...By Sandi Wong, Assistant Editor Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has...
BioCentury | Jan 30, 2021
Regulation

EMA’s clearance of AZ vaccine in all adults leaves countries option to restrict among older adults

...suggesting a 59.5% vaccine efficacy rate.The update is roughly comparable to data published in The Lancet...
...but drew its conclusion from the 86% of subjects received doses within the approved range.The Lancet...
BioCentury | Jan 27, 2021
Product Development

Size of elderly populations in COVID-19 vaccine trials: Data Byte

...elderly individuals remains an open question. The Lancet...
...Sources: New England Journal of Medicine and Lancet Stephen...
BioCentury | Dec 30, 2020
Regulation

U.K. pairs green light for AZ-Oxford vaccine with aggressive distribution scheme to prioritize saving more lives

...cases that was as long as 12 weeks in AZ’s clinical trials. Data published in The Lancet...
...was the observation that a longer interval between standard doses led to greater efficacy. The Lancet...
BioCentury | Dec 11, 2020
Product Development

AZ and Oxford paper spotlights the swerves on the road to pooled vaccine efficacy readout

...details the unplanned protocol shifts complicating the pooled efficacy analysis of AstraZeneca and Oxford’s AZD1222.The Lancet...
Items per page:
1 - 10 of 800
BioCentury | Feb 23, 2021
Product Development

U.K. adds to real-world data backing flexible COVID vaccine schedule

...findings, published as a preprint in The Lancet, are consistent with Friday’s correspondence in The Lancet...
BioCentury | Feb 20, 2021
Product Development

More evidence it’s okay to delay second dose of COVID vaccines

...first and second doses.One study, reported Friday by Chaim Sheba Medical Centre and Tel Aviv University researchers in The Lancet...
...from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) rises quickly after the first dose. The second paper, also published in Lancet...
...to the window when vaccine-induced immune responses were building. New AstraZeneca dataAlso on Friday, a separate Lancet...
BioCentury | Feb 6, 2021
Product Development

AstraZeneca’s vaccine results suggest a modality-independent dip in protection against variants

...against symptomatic disease caused by the B.1.1.7 (501Y.V1) variant first identified in the U.K. in a Lancet ...
...B.1.1.7 and 95.6% against the original variant.The variant-based paper also support findings reported Monday in a Lancet paper...
BioCentury | Feb 4, 2021
Product Development

Vaxart falls on mixed Phase I readout for COVID-19 vaccine; plus BMS-Rockefeller mAb cocktail deal and vaccine updates for Sputnik V, Novavax, Bharat-Ocugen and Sinovac

...registered the heterologous adenoviral vector vaccine to 18. The new authorizations were announced a day after The Lancet...
BioCentury | Feb 4, 2021
Product Development

AstraZeneca’s Phase III vaccine reduces symptomatic cases, not asymptomatic spread

...problem of asymptomatic spread. The results, according to a Lancet...
...the boosterdose,” the authors wrote in the Lancet...
...down slightly from the 70.4% reported in Lancet...
BioCentury | Feb 3, 2021
Product Development

Sputnik V on par with other COVID-19 vaccines before and after boost

...By Sandi Wong, Assistant Editor Phase III data in The Lancet revealed Russian COVID-19 vaccine Sputnik V has...
BioCentury | Jan 30, 2021
Regulation

EMA’s clearance of AZ vaccine in all adults leaves countries option to restrict among older adults

...suggesting a 59.5% vaccine efficacy rate.The update is roughly comparable to data published in The Lancet...
...but drew its conclusion from the 86% of subjects received doses within the approved range.The Lancet...
BioCentury | Jan 27, 2021
Product Development

Size of elderly populations in COVID-19 vaccine trials: Data Byte

...elderly individuals remains an open question. The Lancet...
...Sources: New England Journal of Medicine and Lancet Stephen...
BioCentury | Dec 30, 2020
Regulation

U.K. pairs green light for AZ-Oxford vaccine with aggressive distribution scheme to prioritize saving more lives

...cases that was as long as 12 weeks in AZ’s clinical trials. Data published in The Lancet...
...was the observation that a longer interval between standard doses led to greater efficacy. The Lancet...
BioCentury | Dec 11, 2020
Product Development

AZ and Oxford paper spotlights the swerves on the road to pooled vaccine efficacy readout

...details the unplanned protocol shifts complicating the pooled efficacy analysis of AstraZeneca and Oxford’s AZD1222.The Lancet...
Items per page:
1 - 10 of 800